Bio-Techne has announced a collaboration to distribute Spear Bio’s advanced SPEAR UltraDetect immunoassays worldwide, with an initial focus on the neurology research market.
This partnership allows Bio-Techne to distribute ultrasensitive immunoassays for low-abundance biomarkers, crucial in Alzheimer’s disease research, such as GFAP, neurofilament light (Nf-L), phosphorylated tau 231 (pTau 231), and phosphorylated tau 217 (pTau 217).
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The alliance is a follow-up to Bio-Techne’s involvement in Spear Bio’s $45m Series A funding round last year.
Bio-Techne protein sciences president Will Geist said: “Partnering with Spear Bio marks an exciting step in our mission to advance biomarker detection in neurodegenerative disease research.
“By leveraging Bio-Techne’s global reach and immunoassay expertise with Spear Bio’s ultrasensitive technology, we are equipping researchers with innovative tools to detect and study critical biomarkers with unmatched precision and sensitivity.”
Spear Bio’s Successive Proximity Extension Amplification Reaction (SPEAR) platform is based on Harvard University-licensed technology.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataAmplified leveraging standard quantitative polymerase chain reaction (qPCR) instrumentation, the platform claims to provide sensitivity exceeding that of existing immunoassay platforms.
Spear Bio is poised to expedite its assay technology deployment, with the support of Bio-Techne’s international presence.
This allows for the identification of biomarkers under conditions that were difficult to analyse.
Spear Bio is initially targeting neurodegenerative diseases, but its technology is said to hold applications in oncology, inflammation, and other areas.
Spear Bio CEO and founder Feng Xuan said: “Our strategic partnership with Bio-Techne represents a transformative opportunity for neurodegenerative disease research.
“By combining Bio-Techne’s global distribution network and market leadership with Spear Bio’s next-generation immunoassay technology, we are empowering researchers worldwide to investigate earlier disease mechanisms, improve patient stratification in clinical trials, and accelerate the development of new treatments for neurological disorders.”
